Mannitol Viaflo Baxter (Mannitol)

Mannitol works by increasing the osmolality of plasma, which draws water from cells and interstitial spaces into the bloodstream. This osmotic shift expands intravascular volume, enhances kidney filtration, and reduces pressure in confined compartments such as the brain and eye.

The dosage of Mannitol Viaflo Baxter is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical response. Healthcare professionals calculate the appropriate infusion rate and total amount for each individual case.

Mannitol’s safety in pregnancy and lactation is not well established, and the pregnancy category is listed as unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made by a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Mannitol is a widely used osmotic diuretic that provides rapid plasma expansion and pressure reduction. Compared with hypertonic saline, Mannitol has a lower sodium load and is less likely to cause hypernatremia, while offering similar efficacy in decreasing intracranial and intraocular pressures.

Mannitol Viaflo Baxter should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required for administration.

Mannitol Viaflo Baxter is administered intravenously by slow infusion through a sterile IV line. The infusion rate and total volume are set by the treating physician, who monitors the patient’s vital signs, urine output, and electrolyte status throughout the procedure.

Serious risks include acute renal failure worsening, pulmonary edema, severe electrolyte disturbances (especially hypernatremia or hypokalemia), anaphylactoid reactions, hemolysis, and profound hypotension. Prompt recognition and supportive management are essential if any of these events occur.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial bleeding, uncontrolled heart failure, or severe renal impairment where fluid removal could be harmful. Clinicians must evaluate each patient’s condition before initiating therapy.